T-cell therapy induced CMRs with no CRS

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
A novel CD19-targeted T-cell therapy induced complete metabolic responses (CMRs) and no cytokine release syndrome (CRS) in patients with B-cell lymphomas in a first-in-human clinical study. All subjects achieving CMR at the 1-month safety and efficacy assessment continued to show CMR at 3 months, investigators reported at... [Read Article]
Print Friendly, PDF & Email

Gene signature might identify patients at risk of CAR T-associated neurotoxicity

Print Friendly, PDF & Email


Attendees at 2018 ASCO Annual Meeting
©ASCO/Zach Boyden-Holmes 2018
A specific gene signature might be able to identify patients at risk of CD19 CAR T-cell associated neurotoxicity, according to results of an exploratory analysis presented at the 2018 ASCO Annual Meeting. The analysis, based on bone marrow samples from patients with relapsed/refractory B-cell acute lymphoblastic... [Read Article]
Print Friendly, PDF & Email

Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomab

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Prior exposure to blinatumomab does not appear to affect the successful manufacture of KTE-C19 or its efficacy in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The clinical benefit of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was preserved regardless of whether patients were exposed to... [Read Article]
Print Friendly, PDF & Email

bb2121 demonstrates durable responses, manageable toxicity in MM

Print Friendly, PDF & Email


Noopur S. Raje, MD
Photo by Andrew D. Bowser
bb2121, the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, induced deep and durable ongoing responses in heavily pretreated multiple myeloma (MM) patients, updated results of a phase 1 study show. At active doses (≥150 x 108 CAR+ T cells), the B-cell maturation antigen (BCMA)-targeted therapy produced... [Read Article]
Print Friendly, PDF & Email

Polatuzumab plus BR improves efficacy in DLBCL

Print Friendly, PDF & Email


Attendees at ASCO 2018
©ASCO/Zach Boyden-Holmes 2018
Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a phase 2 study. By contrast, there were no such improvements in a cohort of follicular lymphoma (FL)... [Read Article]
Print Friendly, PDF & Email

Two agents could take AML therapy in new directions

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Rodney White 2018
Two agents targeting novel pathways in myeloid malignancies—mivebresib and bencentinib—are showing promise in early studies, according to a speaker at the 2018 ASCO Annual Meeting. “Both BET and AXL inhibition appear to be new and exciting targets in myeloid malignancies,” said Alice S. Mims, MD, and both... [Read Article]
Print Friendly, PDF & Email

Single-agent acalabrutinib ‘impressive’ in patients with WM

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD, reported at the 2018 ASCO Annual Meeting. The BTK inhibitor was effective in both treatment-naïve and relapsed/refractory patients, with overall response rates for both groups in excess of 90%,... [Read Article]
Print Friendly, PDF & Email

Encouraging early results for CB-derived NK cells in MM

Print Friendly, PDF & Email


Attendees at ASCO 2018
©ASCO/Todd Buchanan 2018
Cord blood (CB) is a viable source of natural killer (NK) cells for adoptive cellular therapy for multiple myeloma (MM), according to a speaker at the 2018 ASCO Annual Meeting. Ex-vivo expanded cord blood NK cells were well tolerated without significant graft-versus-host disease (GVHD) or cytokine release syndrome... [Read Article]
Print Friendly, PDF & Email